Boston Scientific (BSX) Shares Rally 1.14% on Strategic $850M Relievant Medsystems Acquisition

Boston Scientific (BSX) shares climbed 0.08% in the latest trading session, marking the third consecutive day of gains and a 1.14% rise over the past three days. The stock reached its highest level since September 2025, with an intraday high of 0.24% above its opening price, reflecting renewed investor confidence.

The rally was driven by the company’s $850 million acquisition of Relievant Medsystems, a developer of spine surgery technologies. The deal expanded Boston Scientific’s portfolio in minimally invasive procedures, integrating platforms like PercuSafe and PercuFuse, which enhance surgical precision. Analysts highlighted the acquisition as a strategic move to strengthen its position in a high-growth segment, with several institutions upgrading price targets and reaffirming “Buy” ratings. UBS raised its target to $66, while BTIG and Mizuho set new benchmarks between $60–$64, underscoring optimism about the company’s long-term prospects.

Product advancements further bolstered sentiment. The FARAPULSE Pulsed Field Ablation system, designed for cardiac rhythm management, demonstrated strong clinical trial results, reinforcing Boston Scientific’s R&D capabilities. Additionally, the upcoming Investor Day on September 20, where management outlined financial goals and operational progress, provided clarity on strategic priorities. These developments, coupled with the CEO’s appointment to CVS Health’s board, signaled alignment with broader healthcare trends and reinforced cross-industry credibility.

Collectively, the acquisition, analyst endorsements, and product innovation positioned Boston Scientific to capitalize on growth in high-margin areas like spinal surgery and cardiac ablation. The stock’s performance reflected investor anticipation of sustained momentum, despite short-term volatility around the Investor Day event. With a diversified portfolio and a focus on minimally invasive technologies, the company appears well-placed to navigate competitive dynamics in the medical device sector.